Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center

About this trial

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.

Eligibility criteria

Qualifiers

Patient ≥ 18 y.o.

Structural Heart Disease: Ischemic Cardiomyopathy

Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation

Disqualifiers

If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation

Myocardial infarction or cardiac surgery within 6 months

Severe mitral regurgitation

Stroke or TIA within 6 months

Trial design

Treatments tested in this trial

  • Ablation-index guided ventricular tachycardia ablation
  • Ventricular tachycardia ablation with no AI-guidance

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Rush University Medical Center

Lead sponsor

University of Michigan

Collaborator

Medical University of South Carolina

Collaborator

Biosense Webster, Inc.

Collaborator

Mayo Clinic

Collaborator

Brigham and Women's Hospital

Collaborator